Open Nav

Please submit your session questions in advance at

Salarius Pharmaceuticals

  • David Arthur, Salarius Pharmaceuticals

Salarius Pharmaceuticals is a clinical-stage biotechnology company focused on developing effective cancer treatments for patients who need them most. Salarius was formed in 2011 after licensing the technology related to their lead compound from the University of Utah. Following formation, Salarius focused on identifying and progressing their lead therapeutic candidate to IND approval. As part of this process, Salarius was able to generate impressive preclinical data that was instrumental in being selected to receive an $18.7M grant from the Cancer Prevention & Research Institute of Texas (CPRIT). Salarius received IND activation from the FDA in March 2018. In 3Q2018 Salarius initiated a Phase 1 clinical trial in Ewing sarcoma and will be opening an additional Phase 1 trial in Advanced Solid Tumors in 1H2019.

  • Date:Monday, February 11
  • Time:11:00 AM - 11:15 AM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Privately Funded Company
  • Submission ID:23522
  • Goal for Presentation:Raise Investor Awareness
  • Company Website:
  • Company HQ City:Houston
  • Company HQ State:Texas
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$9M
  • Size of Last Investment Round:$6.4M
  • CEO/Top Company Official:David Arthur
  • Year Founded:2011
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:Seclidemstat
  • Development Phase of Primary Product:Phase I
David Arthur
Salarius Pharmaceuticals